On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

(2011) Paul Mitchell   CURRENT MEDICAL RESEARCH AND OPINION

Bevacizumab for Retinopathy of Prematurity

(2011) James D. Reynolds   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

(2011) Helen A. Mintz-Hittner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monitoring systemic complications of intraocular medications

(2010) Jose S. Pulido   CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE

Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database

(2010) Jonathan A. Micieli et al.   CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE

The Effect of Methotrexate on Corneal Neovascularization in Rabbits

(2010) Yong-Soo Byun et al.   CORNEA

Vascular Endothelial Growth Factor and Its High-Affinity Receptor (VEGFR-2) Are Highly Expressed in the Human Forebrain and Cerebellum During Development

(2010) Loïc Sentilhes et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Serum Concentration of Bevacizumab after Intravitreal Injection in Experimental Branch Retinal Vein Occlusion

(2010) Lan-Hsin Chuang et al.   OPHTHALMIC RESEARCH

VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity

(2008) C Pieh et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

VEGF Inhibition and Renal Thrombotic Microangiopathy

(2008) Vera Eremina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vitreous Levels of Stromal Cell–Derived Factor 1 and Vascular Endothelial Growth Factor in Patients with Retinopathy of Prematurity

(2007) Kenan Sonmez et al.   OPHTHALMOLOGY